{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:13Z","timestamp":1792612273329,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024068","name":"Witten\/Herdecke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bbr.2025.115551","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T04:28:59Z","timestamp":1742790539000},"page":"115551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The mechanistic role of piracetam in the management of vascular dementia"],"prefix":"10.1016","volume":"486","author":[{"given":"Hayder M.","family":"Al-kuraishy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-492X","authenticated-orcid":false,"given":"Duaa","family":"Eliwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbr.2025.115551_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1527-3458.2005.tb00268.x","article-title":"Piracetam: a review of pharmacological properties and clinical uses","volume":"11","author":"Winblad","year":"2005","journal-title":"CNS Drug Rev."},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/11319230-000000000-00000","article-title":"Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders","volume":"70","author":"Malykh","year":"2010","journal-title":"Drugs"},{"issue":"6 Pt A","key":"10.1016\/j.bbr.2025.115551_bib3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.bbadis.2018.03.014","article-title":"New therapeutic activity of metabolic enhancer piracetam in treatment of neurodegenerative disease: Participation of caspase independent death factors, oxidative stress, inflammatory responses and apoptosis","volume":"1864","author":"Verma","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"2","key":"10.1016\/j.bbr.2025.115551_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1113\/JP280873","article-title":"Structural basis for positive allosteric modulation of AMPA and kainate receptors","volume":"600","author":"Frydenvang","year":"2022","journal-title":"J. Physiol."},{"issue":"12","key":"10.1016\/j.bbr.2025.115551_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11123310","article-title":"Effects of smart drugs on cholinergic system and non-neuronal acetylcholine in the mouse hippocampus: histopathological approach","volume":"11","author":"Satoh","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib6","first-page":"11","article-title":"Neuroprotective effect of piracetam and vincamine in a rat model of haloperidol-induced parkinson's disease","volume":"42","author":"Sheref","year":"2022","journal-title":"Bull. Egypt. Soc. Physiol. Sci."},{"issue":"9","key":"10.1016\/j.bbr.2025.115551_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10090611","article-title":"Neuroprotective effect of piracetam against cocaine-induced neuro epigenetic modification of DNA methylation in astrocytes","volume":"10","author":"Sivalingam","year":"2020","journal-title":"Brain Sci."},{"issue":"10","key":"10.1016\/j.bbr.2025.115551_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1258\/ebm.2012.012128","article-title":"A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons","volume":"237","author":"Bravo-Mart\u00ednez","year":"2012","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.bbr.2025.115551_bib9","doi-asserted-by":"crossref","DOI":"10.5812\/ijpbs.59421","article-title":"Effects of piracetam as an adjuvant therapy on attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Alavi","year":"2021","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"issue":"12","key":"10.1016\/j.bbr.2025.115551_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121563","article-title":"Piracetam as a therapeutic agent for doxorubicin-induced cognitive deficits by enhancing cholinergic functions and reducing neuronal inflammation, apoptosis, and oxidative stress in rats","volume":"15","author":"Mani","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbr.2025.115551_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.125178","article-title":"Physicochemical investigations of nootropic drug piracetam for enhanced solubilization as nano drug carrier under the influence of single and mixed micellar formulations: an optimized approach towards drug delivery","volume":"407","author":"Huzaifa Ihsan","year":"2024","journal-title":"J. Mol. Liq."},{"issue":"8","key":"10.1016\/j.bbr.2025.115551_bib12","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00221-024-06868-x","article-title":"Piracetam reduces oxidative stress and mitochondrial function impairment in an in vitro model of vascular dementia","volume":"242","author":"Liu","year":"2024","journal-title":"Exp. Brain Res."},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0254-6272(11)60036-8","article-title":"Clinical research on comprehensive treatment of senile vascular dementia","volume":"31","author":"Chen","year":"2011","journal-title":"J. Tradit. Chin. Med."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/STROKEAHA.112.670844","article-title":"Prevalence of poststroke cognitive impairment: South London Stroke Register 1995-2010","volume":"44","author":"Douiri","year":"2013","journal-title":"Stroke"},{"issue":"5-6","key":"10.1016\/j.bbr.2025.115551_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000091434","article-title":"Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study","volume":"21","author":"Sachdev","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"11","key":"10.1016\/j.bbr.2025.115551_bib16","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jalz.2018.06.3061","article-title":"Stroke and dementia risk: a systematic review and meta-analysis","volume":"14","author":"Ku\u017ama","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/ciia.2006.1.3.229","article-title":"Vascular dementia: prevention and treatment","volume":"1","author":"McVeigh","year":"2006","journal-title":"Clin. Inter. Aging"},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13311-021-01170-y","article-title":"Vascular cognitive impairment (VCI)","volume":"19","author":"Rundek","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.bbr.2025.115551_bib19","article-title":"Vascular dementia subtypes, pathophysiology, genetics, neuroimaging, biomarkers, and treatment updates along with its association with Alzheimer's dementia and diabetes mellitus","volume":"69","author":"Prajjwal","year":"2023","journal-title":"Dis. Mon."},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-220012","article-title":"Prevalence of dementia and main subtypes in Mexico: the study on aging and dementia in Mexico (SADEM)","volume":"89","author":"Juarez-Cedillo","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbr.2025.115551_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116662","article-title":"Mixed dementia: neglected clinical entity or nosographic artifice?","volume":"410","author":"Fierini","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbr.2025.115551_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.727590","article-title":"Neurovascular alterations in vascular dementia: emphasis on risk factors","volume":"13","author":"Lecordier","year":"2021","journal-title":"Front. Aging Neurosci."},{"issue":"8","key":"10.1016\/j.bbr.2025.115551_bib23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1161\/ATVBAHA.119.311908","article-title":"Epidemiology of vascular dementia","volume":"39","author":"Wolters","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbr.2025.115551_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.720715","article-title":"Vascular dementia and underlying sex differences","volume":"13","author":"Akhter","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bbr.2025.115551_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577109","article-title":"A challenging diagnosis of reversible \"vascular\" dementia: cerebral amyloid angiopathy-related inflammation","volume":"338","author":"Poli","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41440-019-0357-9","article-title":"Roles of vascular risk factors in the pathogenesis of dementia","volume":"43","author":"Takeda","year":"2020","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.bbr.2025.115551_bib27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/fcp.12473","article-title":"Neuroprotective effects of zafirlukast, piracetam and their combination on L-Methionine-induced vascular dementia in rats","volume":"33","author":"Fayez","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbr.2025.115551_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10571-007-9165-x","article-title":"Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats","volume":"28","author":"He","year":"2008","journal-title":"Cell. Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.bbr.2025.115551_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10571-014-0037-x","article-title":"Piracetam ameliorated oxygen and glucose deprivation-induced injury in rat cortical neurons via inhibition of oxidative stress, excitatory amino acids release and P53\/Bax","volume":"34","author":"He","year":"2014","journal-title":"Cell. Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.bbr.2025.115551_bib30","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20198371","article-title":"Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis\/autophagy-related genes associated with the activation of the Akt\/mTOR signaling pathway","volume":"52","author":"Xu","year":"2019","journal-title":"Braz. J. Med Biol. Res"},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0011-393X(95)85030-9","article-title":"Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia","volume":"56","author":"Aguglia","year":"1995","journal-title":"Curr. Ther. Res."},{"issue":"5(Special","key":"10.1016\/j.bbr.2025.115551_bib32","first-page":"2405","article-title":"Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction","volume":"33","author":"Zongfang","year":"2020","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.bbr.2025.115551_bib33","first-page":"231","article-title":"Effect of the xingding allied piracetam injection on improvement of cognitive function in patients with vascular dementia","volume":"53","author":"Chen","year":"2005","journal-title":"Chin. J. Tissue Eng. Res."},{"issue":"4","key":"10.1016\/j.bbr.2025.115551_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000057700","article-title":"Clinical efficacy of piracetam in cognitive impairment: a meta-analysis","volume":"13","author":"Waegemans","year":"2002","journal-title":"Dement Geriatr. Cogn. Disord."},{"issue":"5","key":"10.1016\/j.bbr.2025.115551_bib35","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00213-018-4867-y","article-title":"The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis","volume":"235","author":"Perng","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2025.115551_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2024.108358","article-title":"Cognitive effects of piracetam in adults with memory impairment: a systematic review and meta-analysis","volume":"243","author":"Gouhie","year":"2024","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"2","key":"10.1016\/j.bbr.2025.115551_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14412\/2074-2711-2022-2-49-55","article-title":"Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders","volume":"14","author":"Dadasheva","year":"2022","journal-title":"Neurol. Neuropsychiatry Psychosom."},{"issue":"4","key":"10.1016\/j.bbr.2025.115551_bib38","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.athoracsur.2006.05.005","article-title":"Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo","volume":"82","author":"Szalma","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.bbr.2025.115551_bib39","first-page":"44","article-title":"Improved mitochondrial function in brain aging and Alzheimer disease\u2013the new mechanism of action of the old metabolic enhancer piracetam","volume":"4","author":"Leuner","year":"2010","journal-title":"Front. Neurosci."},{"issue":"12","key":"10.1016\/j.bbr.2025.115551_bib40","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.neurobiolaging.2005.10.004","article-title":"Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia","volume":"27","author":"Rom\u00e1n","year":"2006","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1590\/S1980-57642008DN10100002","article-title":"Vascular dementia and the cholinergic pathways","volume":"1","author":"Engelhardt","year":"2007","journal-title":"Dement. Neuropsychol."},{"issue":"7","key":"10.1016\/j.bbr.2025.115551_bib42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/aps.2009.82","article-title":"Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment","volume":"30","author":"Wang","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.bbr.2025.115551_bib43","article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis","author":"Shenkin","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib44","first-page":"20","article-title":"Reversal of phenytoin-induced impairment of spontaneous alternation by piracetam in mice: Involvement of cholinergic system","volume":"36","author":"Shahid","year":"2004","journal-title":"Indian J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbr.2025.115551_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/221155600302150302105355","article-title":"Modulation Effects of piracetam and Ginkgo biloba on the cognitive and working memory functions: Psychometric study","volume":"3","author":"Alkuraishy","year":"2014","journal-title":"Curr. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib46","first-page":"299","article-title":"Neuroprotective therapy with citicoline and piracetam at acute cerebrovascular disease: clinical and psychosomatic effects","volume":"46","author":"Sokolova","year":"2021","journal-title":"Fabad J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/metabo12010004","article-title":"Metabolic influences modulating erythrocyte deformability and eryptosis","volume":"12","author":"Brun","year":"2021","journal-title":"Metabolites"},{"issue":"2","key":"10.1016\/j.bbr.2025.115551_bib48","first-page":"65","article-title":"Deformability of erythrocytes and oxidative damage in alzheimer disease","volume":"37","author":"Yerer","year":"2012","journal-title":"\u00c7ukurova \u00dcniversitesi T\u0131p Fak. \u00fcltesi Derg. (J. Cukurova Univ. Fac. Med.)"},{"issue":"3","key":"10.1016\/j.bbr.2025.115551_bib49","article-title":"Relationship between red cell deformability and shear stress in conditions of low shear rate in vascular dementia","volume":"41","author":"Kowal","year":"2002","journal-title":"Acta Clin. Croat."},{"issue":"4","key":"10.1016\/j.bbr.2025.115551_bib50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/CH-168047","article-title":"Vascular dysfunction-associated with Alzheimer\u2019s disease","volume":"64","author":"Carelli-Alinovi","year":"2016","journal-title":"Clin. Hemorheol. Microcirc."},{"issue":"16","key":"10.1016\/j.bbr.2025.115551_bib51","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/nu14163367","article-title":"Nootropics as cognitive enhancers: types, dosage and side effects of smart drugs","volume":"14","author":"Mal\u00edk","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib52","doi-asserted-by":"crossref","DOI":"10.5455\/njppp.2012.v2.i1.9","article-title":"The role of piracetam in treatment of sickle cell anemia","volume":"2","author":"Mostafa","year":"1970","journal-title":"Natl. J. Physiol. Pharm. Pharmacol."},{"issue":"07","key":"10.1016\/j.bbr.2025.115551_bib53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-0031-1281523","article-title":"Effect of systemic piracetam treatment on flap survival and vascular endothelial growth factor expression after ischemia-reperfusion injury","volume":"27","author":"Tuncer","year":"2011","journal-title":"J. Reconstr. Microsurg."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40478-023-01590-1","article-title":"Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairment","volume":"11","author":"Rajeev","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbr.2025.115551_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-011-0925-9","article-title":"Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts","volume":"123","author":"Okamoto","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.bbr.2025.115551_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ncn3.124","article-title":"Chronic cerebral hypoperfusion and dementia","volume":"2","author":"Yata","year":"2014","journal-title":"Neurol. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.bbr.2025.115551_bib57","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/jnr.23777","article-title":"Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease","volume":"95","author":"Daulatzai","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016567","article-title":"The influence of chronic cerebral hypoperfusion on cognitive function and amyloid \u03b2 metabolism in APP overexpressing mice","volume":"6","author":"Yamada","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bbr.2025.115551_bib59","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/brain.2020.0785","article-title":"Regional disconnection in Alzheimer dementia and amyloid-positive mild cognitive impairment: association between EEG functional connectivity and brain glucose metabolism","volume":"10","author":"Smailovic","year":"2020","journal-title":"Brain Connect."},{"issue":"16","key":"10.1016\/j.bbr.2025.115551_bib60","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.3390\/jcm11164742","article-title":"A study on the pathogenesis of vascular cognitive impairment and dementia: the chronic cerebral hypoperfusion hypothesis","volume":"11","author":"Yu","year":"2022","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bbr.2025.115551_bib61","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.3390\/ijms22126285","article-title":"Nxp031 improves cognitive impairment in a chronic cerebral hypoperfusion-induced vascular dementia rat model through nrf2 signaling","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbr.2025.115551_bib62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2016.10.006","article-title":"Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats","volume":"246","author":"Yao","year":"2016","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.bbr.2025.115551_bib63","doi-asserted-by":"crossref","first-page":"10052","DOI":"10.1038\/s41598-017-10283-4","article-title":"S)-Oxiracetam is the active ingredient in oxiracetam that alleviates the cognitive impairment induced by chronic cerebral hypoperfusion in rats","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2025.115551_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuroscience.2019.07.015","article-title":"Protective role of levetiracetam against cognitive impairment and brain white matter damage in mouse prolonged cerebral hypoperfusion","volume":"414","author":"Inaba","year":"2019","journal-title":"Neuroscience"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432825001378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432825001378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T09:18:34Z","timestamp":1763803114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432825001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":64,"alternative-id":["S0166432825001378"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2025.115551","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mechanistic role of piracetam in the management of vascular dementia","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2025.115551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115551"}}